Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
04:01pm, Tuesday, 09'th Apr 2024
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
10:36am, Monday, 01'st Apr 2024
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 22'nd Mar 2024
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
09:02pm, Tuesday, 19'th Mar 2024
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
04:02pm, Tuesday, 19'th Mar 2024
Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
04:02pm, Wednesday, 13'th Mar 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
10:25am, Monday, 12'th Feb 2024
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company?
Poster presentation unveils Corvus' next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications Poster presentation unveils Corvus' next-generatio
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
05:00pm, Tuesday, 23'rd Jan 2024
BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. M
What Makes Corvus (CRVS) a New Buy Stock
01:32pm, Monday, 11'th Dec 2023
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
12:00pm, Saturday, 09'th Dec 2023
Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need fo
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
11:18am, Thursday, 07'th Dec 2023
Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
11:16am, Tuesday, 21'st Nov 2023
Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2023 Earnings Conference Call Transcript
10:46pm, Tuesday, 07'th Nov 2023
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Zack Kubow - Real Chemistry Leiv Lea - CFO Richard Miller - CEO Jim Rosenb
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
04:01pm, Tuesday, 07'th Nov 2023
Protocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell lymphoma (PTCL); multiple sites preparing to initiate trial enrollment
